Summary

The 7 major spondylolisthesis markets reached a value of US$ 17.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 29.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.79% during 2024-2034.

The spondylolisthesis market has been comprehensively analyzed in IMARC's new report titled "Spondylolisthesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spondylolisthesis refers to a medical disorder in which one of the vertebrae in the spinal column slides out of its proper position onto the vertebra below it. This can occur in any part of the spine, but generally, it takes place in the lower back (lumbar spine). The prominent symptoms of the ailment include severe back pain or nerve congestion, resulting in leg discomfort or numbness. Individuals suffering from spondylolisthesis may also experience muscle spasms in the hamstring (back thigh muscles), difficulty walking or standing for long periods, back stiffness, pain while bending over, weakness or tingling in the foot, etc. In severe cases, this condition may impair a person's quality of life by limiting mobility and impacting emotional well-being. The diagnosis of the illness is mainly made by reviewing the reported clinical features, medical history, and a physical test. A healthcare provider may also perform numerous other examinations, such as spinal X-rays, magnetic resonance imaging, computed tomography, etc., to look for misplaced bones or rule out further possible soft tissue diseases.

The rising cases of bone fractures or cracks which weaken the vertebrae, thereby enhancing their likelihood of slipping forward, backward, or over a bone below, are primarily driving the spondylolisthesis market. In addition to this, the expanding geriatric population, who are more prone to degenerative spine conditions due to wear and tear on the spine, is also bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, such as ibuprofen and naproxen, which target the intervertebral joints and the nerve root to reduce pain, is acting as another significant growth-inducing factor. In line with this, the inflating application of epidural steroid injections that can be injected directly into the affected area to diminish swelling and control pressure on the larger nerves quickly is further propelling the market growth. Additionally, the emerging popularity of non-fusion spinal decompression surgery for treating the ailment since it aids in preserving the motion of the spine, lowering the risk of adjacent segment disease, and relieving neurological symptoms, is expected to drive the spondylolisthesis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the spondylolisthesis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spondylolisthesis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spondylolisthesis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the spondylolisthesis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the spondylolisthesis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current spondylolisthesis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the spondylolisthesis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the spondylolisthesis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the spondylolisthesis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of spondylolisthesis across the seven major markets?
What is the number of prevalent cases (2018-2034) of spondylolisthesis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of spondylolisthesis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with spondylolisthesis across the seven major markets?
What is the size of the spondylolisthesis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of spondylolisthesis?
What will be the growth rate of patients across the seven major markets?

Spondylolisthesis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for spondylolisthesis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spondylolisthesis market?
What are the key regulatory events related to the spondylolisthesis market?
What is the structure of clinical trial landscape by status related to the spondylolisthesis market?
What is the structure of clinical trial landscape by phase related to the spondylolisthesis market?
What is the structure of clinical trial landscape by route of administration related to the spondylolisthesis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Spondylolisthesis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Spondylolisthesis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Spondylolisthesis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Spondylolisthesis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Spondylolisthesis - Unmet Needs

10 Spondylolisthesis - Key Endpoints of Treatment

11 Spondylolisthesis - Marketed Products
11.1 List of Spondylolisthesis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Spondylolisthesis - Pipeline Drugs
12.1 List of Spondylolisthesis Pipeline Drugs Across the Top 7 Markets
12.1.1 NVD001 - Novadip Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AK 1320 MS - Asahi Kasei Pharma Corp
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Spondylolisthesis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Spondylolisthesis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Spondylolisthesis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Spondylolisthesis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Spondylolisthesis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Spondylolisthesis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Spondylolisthesis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Spondylolisthesis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Spondylolisthesis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Spondylolisthesis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Spondylolisthesis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Spondylolisthesis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Spondylolisthesis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Spondylolisthesis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Spondylolisthesis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Spondylolisthesis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Spondylolisthesis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Spondylolisthesis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Spondylolisthesis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Spondylolisthesis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Spondylolisthesis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Spondylolisthesis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Spondylolisthesis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Spondylolisthesis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Spondylolisthesis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Spondylolisthesis - Access and Reimbursement Overview

16 Spondylolisthesis - Recent Events and Inputs From Key Opinion Leaders

17 Spondylolisthesis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Spondylolisthesis Market – Strategic Recommendations

19 Appendix